ArticlePreventive medicine reports2022
Barriers to human papillomavirus (HPV) vaccination among young adults, aged 18-35.
Article in Preventive medicine reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Motivated by mortality:Exploratory research in clinical and social pharmacy · 2026Article
- Knowledge, Attitudes, and Behaviors Regarding HPV Vaccination and Self-Sampling Among US Young Adults.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Article
- Expanding HPV prevention across the life course: evidence on vaccine effectiveness in adults.Frontiers in public health · 2026Review
- Article
- Role of cyberchondria severity in the relationship between HPV awareness and vaccination status among adult women.BMC public health · 2025Article
- HPV Vaccination in the U.S. Midwest: Barriers and Facilitators of Initiation and Completion in Adolescents and Young Adults.Vaccines · 2025Article
- siRNA and mRNA-Based Preventive and Therapeutic Strategies for HPV-Induced Cervical Cancer.Advanced pharmaceutical bulletin · 2025Review
- Barriers in the prevention and early detection of human papillomavirus in Latin America.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- Systematic Review and Meta-Analysis of Human Papillomavirus Prevalence and Genotypic Disparities Among Human Immunodeficiency Virus-Positive Women in Africa.Journal of clinical medicine · 2025Review
- HPV Vaccination Knowledge and Decision-Making Among Adults 27 to 45 Years: A Large Online Survey.Laryngoscope investigative otolaryngology · 2025Article
- Race/Ethnicity, Human Papillomavirus Vaccination Status, and Papanicolaou Test Uptake Among 27-45-Year-Old Women: A Cross-Sectional Analysis of 2019-2022 Behavioral Risk Factor Surveillance System Data.Women's health reports (New Rochelle, N.Y.) · 2025Article
- Article
- Human papillomavirus vaccination hesitancy among young girls in Ethiopia: factors and barriers to uptake.Frontiers in public health · 2025Article
- Perceived barriers and facilitators to HPV vaccination: Insights from focus groups with unvaccinated mid-adults in a U.S. medically underserved area.Human vaccines & immunotherapeutics · 2024Article
- HPV Vaccines Among University Students: Understanding Barriers and Facilitators of Vaccine Uptake.Vaccines · 2024Article
- Article
- Identifying System-Level Strategies to Engage in HPV Prevention Across Oral Health and Primary Care Settings.Vaccines · 2024Article
- Demographic Influences on Adult HPV Vaccination: Results from a Cross-Sectional Survey in Tennessee.Healthcare (Basel, Switzerland) · 2024Article
- Examining HPV vaccination behavior among young adults: Insights from applying the Health Belief Model.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the United States (US), an estimated 35,900 human papillomavirus (HPV)-related cancers are diagnosed annually. HPV vaccines are projected to eliminate ∼90% of these cancers. Routine vaccination is recommended at age 11-12 with "catch-up" vaccination through age 26 and shared clinical decision making for ages 27-45. However, vaccine uptake has been slow with many young adults remaining unvaccinated. This study examined barriers to HPV vaccination among individuals aged 18-35 years and assessed likelihood of future HPV vaccination. Age-eligible participants (n = 499) recruited through Facebook advertisements, Facebook posts, and clinics (6/2019-3/2020) completed an online survey. Descriptive statistics and bivariate analysis examined HPV vaccine barriers and intent. Logistic regression models examined predictors of HPV vaccine intent. Most (57.1%) reported they were not at all likely to get vaccinated for HPV in the future. Lower intent was associated with belief that the vaccine is not necessary (aOR: 0.134, 95% CI: 0.073, 0.246) and not safe (aOR: 0.312, 95% CI: 0.126, 0.773). Intent was positively associated with the belief that health insurance would not cover vaccination (aOR: 2.226, 95% CI: 1.070, 4.631). Provider recommendation was not significantly associated with vaccine intention. This study highlights challenges to HPV vaccine uptake for young adults. Though several successful interventions exist, most target adolescents and their parents or providers. Future steps should use this evidence to inform development of targeted interventions to increase HPV vaccine intention and uptake in adults, ultimately reducing the burden of HPV-related cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.